RESUMO
In recent decades, following the spread of obesity, metabolic dysfunction has come to represent the leading cause of liver disease. The classical clinical presentation of the cirrhotic patient has, therefore, greatly changed, with a dramatic increase in subjects who appear overweight or obese. Due to an obesogenic lifestyle (lack of physical activity and overall malnutrition, with an excess of caloric intake together with a deficit of proteins and micronutrients), these patients frequently develop a complex clinical condition defined as sarcopenic obesity (SO). The interplay between cirrhosis and SO lies in the sharing of multiple pathogenetic mechanisms, including malnutrition/malabsorption, chronic inflammation, hyperammonemia and insulin resistance. The presence of SO worsens the outcome of cirrhotic patients, affecting overall morbidity and mortality. International nutrition and liver diseases societies strongly agree on recommending the use of food as an integral part of the healing process in the comprehensive management of these patients, including a reduction in caloric intake, protein and micronutrient supplementation and sodium restriction. Based on the pathophysiological paths shared by cirrhosis and SO, this narrative review aims to highlight the nutritional interventions currently advocated by international guidelines, as well as to provide hints on the possible role of micronutrients and nutraceuticals in the treatment of this multifaceted clinical condition.
Assuntos
Hepatopatias , Desnutrição , Sarcopenia , Humanos , Sarcopenia/tratamento farmacológico , Obesidade/terapia , Obesidade/tratamento farmacológico , Cirrose Hepática/terapia , Cirrose Hepática/tratamento farmacológico , Hepatopatias/tratamento farmacológico , Desnutrição/tratamento farmacológico , Micronutrientes/uso terapêuticoRESUMO
Protein diets are required for the normal development of the reproductive system and their inadequacy or deficiency might have hazardous functional complications during maturational and developmental stages. The study was carried out to evaluate the effect of selenium (Se) and zinc (Zn) supplementation on the male and female reproductive organs of rats with postnatal protein malnutrition. Male and female weanling rats were randomly assigned to six groups respectively. The adequate protein diet rats were fed with 16% casein diet while the protein malnourished diet (PMD) rats were fed with 5% casein diet. After the 8th week of feeding, Se (sodium selenite; Na2SeO3) and Zn (zinc sulfate; ZnSO4·7H2O) were supplemented for 3 weeks. The growth curve of body weights, lipid profile, testosterone and progesterone level, Na+-K+-ATPase activity, oxidative stress, and antioxidant status were evaluated. The results showed that PMD reduced the body weights of male and female rats. It also reduced the activities of catalase and glutathione peroxidase in the testes, but reductions in superoxide dismutase and glutathione-S-transferase activities, glutathione, vitamins C and E, testosterone, and progesterone levels were observed in both the testes and ovaries. Furthermore, PMD increased the nitric oxide level in both organs and altered the plasma lipid profiles in both sexes. Se and Zn supplementation, however, restored almost all the alterations observed in all the parameters analyzed. In conclusion, Se and Zn supplementation protects the male and female reproductive organs of rats against postnatal protein malnutrition.
Assuntos
Desnutrição , Selênio , Feminino , Ratos , Masculino , Animais , Selênio/farmacologia , Zinco/farmacologia , Caseínas , Progesterona , Antioxidantes/farmacologia , Antioxidantes/metabolismo , Suplementos Nutricionais , Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Peso Corporal , Desnutrição/tratamento farmacológico , Testosterona , LipídeosRESUMO
BACKGROUND: Sulfadoxine-pyrimethamine (SP) antimalarial therapy has been suggested to potentially increase the birth weight of infants in pregnant women in sub-Saharan Africa, independently of malarial infection. Here, we utilized female intestinal organoid-derived cells cultured within microfluidic Organ Chips to investigate whether SP could directly impact intestinal function and thereby improve the absorption of essential fats and nutrients crucial for fetal growth. METHODS: Using a human organ-on-a-chip model, we replicated the adult female intestine with patient organoid-derived duodenal epithelial cells interfaced with human intestinal endothelial cells. Nutrient-deficient (ND) medium was perfused to simulate malnutrition, resulting in the appearance of enteric dysfunction indicators such as villus blunting, reduced mucus production, impaired nutrient absorption, and increased inflammatory cytokine secretion. SP was administered to these chips in the presence or absence of human peripheral blood mononuclear cells (PBMCs). FINDINGS: Our findings revealed that SP treatment effectively reversed multiple intestinal absorptive abnormalities observed in malnourished female Intestine Chips, as validated by transcriptomic and proteomic analyses. SP also reduced the production of inflammatory cytokines and suppressed the recruitment of PBMCs in ND chips. INTERPRETATION: Our results indicate that SP could potentially increase birth weights by preventing enteric dysfunction and suppressing intestinal inflammation. This underscores the potential of SP as a targeted intervention to improve maternal absorption, subsequently contributing to healthier fetal growth. While SP treatment shows promise in addressing malabsorption issues that can influence infant birth weight, we did not model pregnancy in our chips, and thus its usefulness for treatment of malnourished pregnant women requires further investigation through clinical trials. FUNDING: The Bill and Melinda Gates Foundation, and the Wyss Institute for Biologically Inspired Engineering at Harvard University, and the HDDC Organoid Core of the P30 DK034854.
Assuntos
Antimaláricos , Desnutrição , Complicações Parasitárias na Gravidez , Sulfadoxina , Adulto , Feminino , Humanos , Gravidez , Peso ao Nascer , Células Endoteliais , Leucócitos Mononucleares , Proteômica , Pirimetamina/farmacologia , Pirimetamina/uso terapêutico , Antimaláricos/uso terapêutico , Combinação de Medicamentos , Intestinos , Desnutrição/complicações , Desnutrição/tratamento farmacológicoRESUMO
OBJECTIVES: Numerous studies describe the role of zinc in the immune system and metabolism. Zinc may influence the pathogenesis and prognosis of cancer. The aim of this study to determine the prevalence of zinc deficiency in patients with cancer. The study's primary objective was to evaluate the frequency of zinc deficiency in White patients with cancer and characterize the clinical factors predisposing individuals to decreased zinc concentration. The study also aimed to estimate the dose of zinc supplementation that would prevent deficiency. METHODS: Retrospective data for this cross-sectional study were analyzed from 300 consecutive white patients diagnosed with neoplastic disease and admitted to a major oncology hospital for treatment. Zinc plasma concentration, nutritional status, body composition, and medical history of ailments and dysphagia were recorded. Supplementation was introduced in patients with zinc deficiency according to the local protocol. Zinc plasma levels were collected at follow-up visits. RESULTS: Zinc deficiency was diagnosed in 68% of the patients. Poor nutritional status was significantly associated with zinc deficiency (low body mass index, weight loss, low albumin level). Low lean body mass (P = 0.003) and adipose tissue (P = 0.045) correlated with zinc deficiency. Patients with zinc deficiency reported dysphagia more frequently than those with normal zinc levels (18 versus 8%; P = 0.03). Squamous cell carcinoma was significantly associated with zinc deficiency (P = 0.043). Oral zinc supplementation resulted in reaching laboratory norms for plasma concentration in only 27% of patients with zinc deficiency and was not dependent on lower (10-15 mg) or higher (25-30 mg) dosing (P > 0.05). CONCLUSIONS: Zinc deficiency is common in cachectic, malnourished patients with cancer. Nutritional guidelines for these patients should include screening for micronutrient deficiencies. Further studies are needed to determine the role, dosage, duration, and form of nutritional supplementation recommended for specific cancer diagnoses.
Assuntos
Transtornos de Deglutição , Desnutrição , Neoplasias , Humanos , Zinco , Estudos Transversais , Estudos Retrospectivos , Estado Nutricional , Desnutrição/epidemiologia , Desnutrição/etiologia , Desnutrição/tratamento farmacológico , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Micronutrientes , População BrancaRESUMO
BACKGROUND & AIMS: The use of oral nutritional supplements (ONS) in the hospital setting is important to reach individual protein and energy goals in patients at risk for malnutrition. Compliance with ONS can be challenging but may be improved by prescribing ONS in smaller portions with medication rounds (MEDPass). We compared the likelihood of meeting energy and protein requirements in patients receiving ONS with MEDPass versus conventional ONS administration. METHODS: The MEDPass Trial is a randomized, controlled, open-label superiority trial conducted on medical and geriatric wards in a University Hospital in Switzerland. The MEDPass group was allocated to receive 50 ml of ONS four times per day with the medication rounds. The control group received ONS per conventional care between the meals. The primary outcome was the percentage of energy in relation to the individual requirement. Secondary outcomes included the coverage of protein intake in relation to the individual requirement, the amount of daily consumed ONS, the course of handgrip strength (HGS), body weight appetite and nausea. Furthermore, we compared 30-day mortality and hospital length of stay (LOS) was studied in medical patients. RESULTS: From November 22nd, 2018 until November 30th, 2021, 204 patients were included in the trial (MEDPass group n = 100, control group n = 104). A total of 203 patients at nutritional risk were analyzed in the intention-to-treat analysis (ITT). Regarding the primary endpoint, there was no difference in the coverage of energy requirement between the MEDPass and control group (82 vs. 85% (Δ -3%, 95%CI -11 to 4%), p = 0.38). Similarly, no differences were found for the secondary outcomes including coverage of protein requirement (101 vs. 104% (Δ -3%, 95% CI -12 -7%), p = 0.57, average daily intake of ONS (170 vs 173 ml (Δ - 3 ml, 95% CI -14 to 8 ml), p = 0.58) and 30-day mortality (3 vs. 8 patients, OR 0.4 (95% CI 0.1-1.4), p = 0.15). The course of HGS, body weight, appetite and nausea did not differ between the groups (p = 0.29, p = 0.14, p = 0.65 and p = 0.94, respectively). The per protocol analysis including 178 patients showed similar results. CONCLUSION: Within this controlled trial setting, we found a high compliance for ONS intake and high coverage of protein requirements but no further improvement when ONS was administered using MEDPass compared to conventional care. MEDPass administration may provide an alternative that is easy to integrate into nursing routines, which may lead to lower workload with cost benefits and reduction of food waste. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03761680.
Assuntos
Desnutrição , Eliminação de Resíduos , Humanos , Idoso , Força da Mão , Suplementos Nutricionais , Desnutrição/tratamento farmacológico , Peso Corporal , Administração Oral , Estado NutricionalRESUMO
During the last few decades, the micronutrient zinc has proven to be an important metal ion for a well-functioning immune system, and thus also for a suitable immune defense. Nowadays, it is known that the main cause of zinc deficiency is malnutrition. In particular, vulnerable populations, such as the elderly in Western countries and children in developing countries, are often affected. However, sufficient zinc intake and homeostasis is essential for a healthy life, as it is known that zinc deficiency is associated with a multitude of immune disorders such as metabolic and chronic diseases, as well as infectious diseases such as respiratory infections, malaria, HIV, or tuberculosis. Moreover, the modulation of the proinflammatory immune response and oxidative stress is well described. The anti-inflammatory and antioxidant properties of zinc have been known for a long time, but are not comprehensively researched and understood yet. Therefore, this review highlights the current molecular mechanisms underlying the development of a pro-/ and anti-inflammatory immune response as a result of zinc deficiency and zinc supplementation. Additionally, we emphasize the potential of zinc as a preventive and therapeutic agent, alone or in combination with other strategies, that could ameliorate infectious diseases.
Assuntos
Doenças Transmissíveis , Malária , Desnutrição , Oligoelementos , Criança , Humanos , Idoso , Zinco/uso terapêutico , Doenças Transmissíveis/tratamento farmacológico , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Malária/tratamento farmacológico , Malária/prevenção & controle , Desnutrição/tratamento farmacológicoRESUMO
Low muscle mass and malnutrition are prevalent conditions among adults of all ages, with any body weight or body mass index, and with acute or chronic conditions, including COVID-19. This article synthesizes the latest research advancements in muscle health and malnutrition, and their impact on immune function, and clinical outcomes. We provide a toolkit of illustrations and scientific information that healthcare professionals can use for knowledge translation, educating patients about the importance of identifying and treating low muscle mass and malnutrition. We focus on the emerging evidence of mitochondrial dysfunction in the context of aging and disease, as well as the cross-talk between skeletal muscle and the immune system. We address the importance of myosteatosis as a component of muscle composition, and discuss direct, indirect and surrogate assessments of muscle mass including ultrasound, computerized tomography, deuterated creatine dilution, and calf circumference. Assessments of muscle function are also included (handgrip strength, and physical performance tests). Finally, we address nutrition interventions to support anabolism, reduce catabolism, and improve patient outcomes. These include protein and amino acids, branched-chain amino acids, with a focus on leucine; ß-hydroxy-ß-methylbutyrate (HMB), vitamin D; n-3 polyunsaturated fatty acids (n-3 PUFA), polyphenols, and oral nutritional supplements. We concluded with recommendations for clinical practice and a call for action on research focusing on evaluating the impact of body composition assessments on targeted nutrition interventions, and consequently their ability to improve patient outcomes.
Assuntos
COVID-19 , Ácidos Graxos Ômega-3 , Desnutrição , Adulto , Aminoácidos/metabolismo , Aminoácidos de Cadeia Ramificada , Creatina , Atenção à Saúde , Suplementos Nutricionais , Ácidos Graxos Ômega-3/metabolismo , Ácidos Graxos Insaturados/metabolismo , Força da Mão , Humanos , Leucina , Desnutrição/tratamento farmacológico , Força Muscular , Músculo Esquelético/fisiologia , Valeratos , Vitamina D/uso terapêuticoRESUMO
INTRODUCCIÓN: En el marco de la metodología ad hoc para evaluar solicitudes de tecnologías sanitarias, aprobada mediante Resolución de Instituto de Evaluación de Tecnologías en Salud e Investigación N° 111-IETSI-ESSALUD-2021, se ha elaborado el presente dictamen, el cual expone la evaluación de la eficacia y seguridad de multivitamínico pediátrico endovenoso que contiene 13 vitaminas para pacientes de 1 año a menores de 12 años que reciben nutrición parenteral. La nutrición parenteral (NP) es una técnica de soporte vital y nutricional en la que los nutrientes se administran por vía endovenosa para aquellos pacientes donde la vía enteral es insuficiente, inadecuada o está contraindicada (Baker et al. 2020). La NP en el paciente pediátrico tiene como objetivo suministrar las demandas específicas de energía y nutrientes manteniendo un balance de energía positivo que permita un crecimiento y desarrollo adecuados procurando evitar tanto la infranutrición como la sobrenutrición (Martínez Costa y Pedrón Giner 2017). Aproximadamente, el 12 % de las prescripciones de NP en las clínicas y hospitales de Lima-Perú, entre enero y junio del 2017, fueron para pacientes pediátricos. La mayoría de prescripciones fueron para neonatos o adultos (Conislla Huaman 2018). METODOLOGÍA: Se llevó a cabo una búsqueda bibliográfica exhaustiva con el objetivo de identificar la mejor evidencia sobre la eficacia y seguridad de multivitamínico pediátrico endovenoso que contiene 13 vitaminas para pacientes de 1 año a menores de 12 años que reciben NP. La búsqueda bibliográfica se realizó en las bases de datos PubMed, The Cochrane Library y LILACS. Asimismo, se realizó una búsqueda manual dentro de las páginas web pertenecientes a grupos que realizan evaluación de tecnologías sanitarias y GPC incluyendo el National Institute for Health and Care Excellence (NICE), la Canadian Agency for Drugs and Technologies in Health (CADTH), el Scottish Medicines Consortium (SMC), el Scottish Intercollegiate Guidelines Network (SIGN), el Institute for Quality and Efficiency in Healthcare (IQWiG por sus siglas en alemán), el Centro Nacional de Excelencia Tecnológica en Salud (CENETEC), la Base Regional de Informes de Evaluación de Tecnologías en Salud de las Américas (BRISA), la OMS, el Ministerio de Salud del Perú (MINSA) y el Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI). Además, se realizó una búsqueda de GPC de las principales sociedades o instituciones especializadas en nutrición, tales como: la European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), la Sociedad Europea de Nutrición Clínica y Metabolismo (ESPEN), la Sociedad Española de Nutrición Clínica y Metabolismo (SENPE), la Sociedad Española de Gastroenterologia, Hepatologia y Nutricion Pediatrica (SEGHNP), la German Society for Nutritional Medicine (GSNM) y la American Society for Parenteral and Enteral Nutrition (ASPEN). Finalmente, se realizó una búsqueda en la página web de registro de ensayos clínicos (EC) www.clinicaltrials.gov, para identificar EC en curso o que no hayan sido publicados aún. RESULTADOS: Luego de la búsqueda bibliográfica hasta noviembre de 2021, se identificaron 5 GPC elaboradas por la European Society for Paediatric Gastroenterology Hepatology and Nutrition / Sociedad Europea de Nutrición Clínica y Metabolismo / la European Society for Paediatric Research / la Chinese Society of Parenteral and Enteral Nutrition (ESPGHAN/ESPEN/ESPR/CSPEN) en el 2018 (Bronsky 2018); la Sociedad Española de Nutrición Clínica y Metabolismo / Sociedad Española de Gastroenterologia, Hepatologia y Nutricion Pediatrica / Sociedad Española de Farmacia Hospitalaria (SENPE/SEGHNP/SEFH) en el 2017 (Pedrón Giner, Cuervas-Mons Vendrell, Galera Martínez, Gómez López, Gomis Muñoz, Irastorza Terradillos, Martínez Costa, Moreno Villares, Pérez-Portabella Maristany, Pozas Del Río, et al. 2017); la German Society for Nutritional Medicine en el 2009 (Fusch et al. 2009); CENETEC en el 2008 (CENETEC 2008) y ASPEN en el 2002 (ASPEN Board of Directors and the Clinical Guidelines Task Force 2002). No se identificaron ETS, ECA o RS de ECA que respondieran la pregunta PICO de interés del presente dictamen y cumplieran con los criterios de elegibilidad planteados reviamente. CONCLUSIÓN: Por lo expuesto, el Instituto de Evaluación de Tecnologías en Salud e Investigación aprueba el uso de multivitamínico pediátrico endovenoso que contiene 13 vitaminas para pacientes de 1 año a menores de 12 años que reciben NP, como producto farmacéutico no incluido en el Petitorio Farmacológico de EsSalud. La vigencia del presente dictamen es de un año, según lo establecido en el Anexo N° 1 y la continuación de dicha aprobación estará sujeta a la evaluación de los resultados obtenidos y de mayor evidencia que pueda surgir en el tiempo.
Assuntos
Humanos , Pré-Escolar , Criança , Nutrição Parenteral/métodos , Suplementos Nutricionais , Desnutrição/tratamento farmacológico , Hipernutrição/tratamento farmacológicoRESUMO
Oral nutritional supplements (ONS) are used to promote catch-up growth in children with undernutrition. We conducted a systematic review and meta-analysis to summarize the evidence of ONS intervention effects on growth for 9-month- to 12-year-old children who were undernourished or at nutritional risk. Eleven randomized controlled trials met the inclusion criteria; trials compared changes in anthropometric measures in children using ONS or ONS + DC (dietary counselling) to measures for those following usual diet or placebo or DC alone. The RCTs included 2287 children without chronic diseases (mean age 5.87 years [SD, 1.35]; 56% boys). At follow-up time points up to 6 months, results showed that children in the ONS intervention group had greater gains in weight (0.423 kg, [95% confidence interval 0.234, 0.613], p < 0.001) and height (0.417 cm [0.059, 0.776], p = 0.022) versus control; greater gains in weight (0.089 kg [0.049, 0.130], p < 0.001) were evident as early as 7-10 days. Longitudinal analyses with repeated measures at 30, 60, and 90 days showed greater gains in weight parameters from 30 days onwards (p < 0.001), a trend towards greater height gains at 90 days (p = 0.056), and significantly greater gains in height-for-age percentiles and Z-scores at 30 and 90 days, respectively (p < 0.05). Similar results were found in subgroup analyses of studies comparing ONS + DC to DC alone. For children with undernutrition, particularly those who were mildly and moderately undernourished, usage of ONS in a nutritional intervention resulted in significantly better growth outcomes when compared to control treatments (usual diet, placebo or DC alone).
Assuntos
Estatura/efeitos dos fármacos , Suplementos Nutricionais , Desnutrição/tratamento farmacológico , Aumento de Peso/efeitos dos fármacos , Administração Oral , Estatura/fisiologia , Criança , Humanos , Aumento de Peso/fisiologiaRESUMO
INTRODUÇÃO: A desnutrição, uma das condições clínicas mais comuns no ambiente hospitalar, é considerada um estado secundário a uma deficiência, causada pelo desequilíbrio energético e frequentemente associada ao aumento de morbimortalidade, aumento de complicações e prognóstico desfavorável dos pacientes internados. Estima-se uma ocorrência em aproximadamente 30% dos pacientes hospitalizados no oeste da Europa e cerca de 50% dos pacientes hospitalizados na América Latina e Brasil. Em um grande estudo epidemiológico multicêntrico, conduzido em 2001, denominado IBRANUTRI, foi identificada no Brasil uma prevalência de desnutrição em pacientes internados de 48,1%, sendo que 12,5% dos pacientes foram classificados como desnutridos graves. Na admissão, foi observada uma frequência de 33,2% de desnutrição. Neste estudo, observou-se que em pacientes com mais de 60 anos a prevalência de desnutrição foi particularmente elevada (52,8% vs 44,7%; OR= 1,39; IC 95% = 1,21-1,58; p ≤ 0,05), assim como em pacientes com infecções (61,4% vs 38,8%; OR = 2,56; IC 95% = 2,24-2,93; p<0,05). Diante deste cenário, estima-se que o envelhecimento da população brasileira se torne em breve um fator ainda mais i
Assuntos
Humanos , Suplementos Nutricionais/provisão & distribuição , Desnutrição/tratamento farmacológico , Pacientes Internados , Sistema Único de Saúde , Brasil , Análise Custo-BenefícioRESUMO
BACKGROUND: Malaria and malnutrition represent major public health concerns worldwide especially in Sub-Sahara Africa. Despite implementation of seasonal malaria chemoprophylaxis (SMC), an intervention aimed at reducing malaria incidence among children aged 3-59 months, the burden of malaria and associated mortality among children below age 5 years remains high in Burkina Faso. Malnutrition, in particular micronutrient deficiency, appears to be one of the potential factors that can negatively affect the effectiveness of SMC. Treating micronutrient deficiencies is known to reduce the incidence of malaria in highly prevalent malaria zone such as rural settings. Therefore, we hypothesized that a combined strategy of SMC together with a daily oral nutrients supplement will enhance the immune response and decrease the incidence of malaria and malnutrition among children under SMC coverage. METHODS: Children (6-59 months) under SMC coverage receiving vitamin A supplementation will be randomly assigned to one of the three study arms (a) SMC + vitamin A alone, (b) SMC + vitamin A + zinc, or (c) SMC + vitamin A + Plumpy'Doz™ using 1:1:1 allocation ratio. After each SMC monthly distribution, children will be visited at home to confirm drug administration and followed-up for 1 year. Anthropometric indicators will be recorded at each visit and blood samples will be collected for microscopy slides, haemoglobin measurement, and spotted onto filter paper for further PCR analyses. The primary outcome measure is the incidence of malaria in each arm. Secondary outcome measures will include mid-upper arm circumference and weight gain from baseline measurements, coverage and compliance to SMC, occurrence of adverse events (AEs), and prevalence of molecular markers of antimalarial resistance comprising Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps. DISCUSSION: This study will demonstrate an integrated strategy of malaria and malnutrition programmes in order to mutualize resources for best impact. By relying on existing strategies, the policy implementation of this joint intervention will be scalable at country and regional levels. TRIAL REGISTRATION: ClinicalTrials.gov NCT04238845 . Registered on 23 January 2020 https://clinicaltrials.gov/ct2/show/NCT04238845.
Assuntos
Antimaláricos , Transtornos da Nutrição Infantil , Malária , Desnutrição , Preparações Farmacêuticas , Antimaláricos/efeitos adversos , Burkina Faso/epidemiologia , Quimioprevenção , Criança , Pré-Escolar , Suplementos Nutricionais , Humanos , Lactente , Malária/diagnóstico , Malária/epidemiologia , Malária/prevenção & controle , Desnutrição/diagnóstico , Desnutrição/tratamento farmacológico , Desnutrição/prevenção & controle , Estações do Ano , Vitamina A/efeitos adversos , ZincoRESUMO
BACKGROUND: Disease-related malnutrition is highly prevalent in hospitalized medical and geriatric inpatients. It is associated with negative outcomes such as muscle wasting, decline of functional status, and increased morbidity and mortality. Oral nutritional supplements (ONS) are frequently used in nutritional therapy to increase intake. However, compliance to ONS is often limited and maybe improved by prescribing ONS in small portions timed with the medication (MEDPass). However, it is unknown whether the MEDPass administration enhances patients' total energy and protein intake. METHODS: The MEDPass Trial is a randomized, controlled, open-label superiority trial. Patients in the MEDPass group receive 50 ml of ONS four times per day, distributed with the medication rounds. Patients in the control group receive ONS between meals. The primary outcome is average daily energy intake (% of calculated daily requirement). For our power analysis, we assumed that administration of ONS in the MEDPass administration mode increases energy intake by at least 10% (i.e., by 200 kcal for an average energy requirement of 2200 kcal/day). Thus, with the inclusion of 200 patients, this trial has 80% power to demonstrate that intervention group patients have an average intake of 2200 kcal/day (SD 500 kcal) versus 2000 kcal/day (SD 500 kcal) in control group patients. Energy and protein intakes from ONS and all food consumed are monitored continuously throughout the hospital stay and are statistically compared to the patient's requirements. Secondary outcomes include average daily protein intake (% of calculated daily requirement), average intake of ONS/day, the course of body weight, handgrip strength, appetite, and nausea. Furthermore, hospital length of stay and 30-day mortality are assessed. The primary statistical analysis will be performed as an intention-to-treat analysis adjusted for the stratification factors used in randomization. DISCUSSION: To our knowledge, this is the first randomized controlled trial assessing total energy and protein intake for the entire hospitalization period in patients receiving MEDPass versus conventional ONS administration. Thus, the MEDPass Trial will fill a gap and answer this relevant clinical question. TRIAL REGISTRATION: ClinicalTrials.gov NCT03761680 . Registered on 3 December 2018. Kofam.ch SNCTP000003191 . Registered on 15 October 2018.
Assuntos
Pacientes Internados , Desnutrição , Administração Oral , Idoso , Suplementos Nutricionais/efeitos adversos , Ingestão de Energia , Força da Mão , Humanos , Desnutrição/diagnóstico , Desnutrição/tratamento farmacológico , Estado Nutricional , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
INTRODUCTION: Malnutrition causes small intestinal atrophy leading to impaired nutrient absorption, zinc deficiency, and intestinal mi-crobiota imbalance affecting appetite. Zinc-only supplementation programs have been shown to be ineffective in reducing the national prevalence of malnutrition. AIM: The aim of this study was to assess the effects of probiotics and zinc in single or combined supplementation on the histological features of ileum and appetite regulating hormone in malnourished rats. MATERIALS AND METHODS: This study included 25 rats aged 8 weeks (weight 150-200 g) divided into 5 groups. Group A served as normal receiving standard diet, group B served as malnourished receiving low calorie diet. Groups C, D, E were pretreated with calo-rie restriction for 14 days to induce malnutrition. The treatment was given for 14 days. Group C was treated with probiotics and zinc combination, group D was treated with probiotics, group E - with zinc. All treatment groups received standard diet at the same time. Ileum sample was taken and subjected to histological preparations using hematoxylin-eosin staining to evaluate villi height and mucosal thickness, blood sample was taken for GLP-1 and ghrelin levels evaluation using ELISA methods. RESULTS: Probiotics and zinc co-supplementation significantly increased villi height and zinc supplementation significantly increased mucosal thickness compared to malnourished rats. GLP-1 levels were significantly increased and ghrelin level was reduced with single or combined supplementation of probiotics and zinc. CONCLUSIONS: Low-calorie feed administered within 14 days successfully changed the profiles of small intestinal histology in rats. Either single or combined administration of probiotics and zinc develop the histological features of ileum and appetite in the malnou- rished rats.
Assuntos
Grelina/metabolismo , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Íleo/patologia , Mucosa Intestinal/patologia , Desnutrição/tratamento farmacológico , Probióticos/farmacologia , Zinco/farmacologia , Animais , Modelos Animais de Doenças , Quimioterapia Combinada , Íleo/efeitos dos fármacos , Íleo/metabolismo , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Masculino , Desnutrição/metabolismo , Desnutrição/patologia , Ratos , Ratos WistarRESUMO
We aimed to determine the efficacy of multiple micronutrient supplementation on the biomarkers of iron, zinc, and vitamin A status across anthropometric status categories in Vietnamese school children. In this 22-week randomised controlled trial, 347 undernourished, normal weight, or overweight/obese children aged 6-9 years were allocated to receive every school day a multiple micronutrient supplement (10 mg iron, 10 mg zinc, 400 µg vitamin A) or a placebo. Haematological indices; circulating ferritin, zinc, and retinol (corrected for inflammation); and C-reactive protein were measured at baseline and 22 weeks. At week 22, linear mixed models showed that mean corpuscular volume increased by 0.3 fL, serum ferritin by 9.1 µg/L, plasma zinc by 0.9 µmol/L, and plasma retinol by 15%, and the prevalence of zinc deficiency decreased by 17.3% points in the intervention group compared to placebo. No intervention effects were found for other haematological indices, or the prevalence of anaemia. Multiple micronutrient supplementation for 22 weeks improved the biomarkers of zinc and vitamin A status and some biomarkers of iron status, and reduced the prevalence of zinc deficiency in Vietnamese school children.Trial registration: This trial was registered on 06/09/2016 at www.anzctr.org.au as ACTRN12616001245482.
Assuntos
Ingestão de Alimentos/fisiologia , Micronutrientes/análise , Anemia/sangue , Anemia/prevenção & controle , Criança , Suplementos Nutricionais , Feminino , Ferritinas/análise , Ferritinas/sangue , Alimentos Fortificados , Humanos , Ferro/sangue , Ferro/metabolismo , Masculino , Desnutrição/tratamento farmacológico , Estado Nutricional , Prevalência , Instituições Acadêmicas , Oligoelementos , Resultado do Tratamento , Vietnã/epidemiologia , Vitamina A/sangue , Vitamina A/metabolismo , Zinco/sangue , Zinco/metabolismoRESUMO
INTRODUCTION: Metabolic and hormonal disorders resulting from chronic liver diseases culminate in increased proteolysis and decreased protein synthesis, which contributes to the development and progression of malnutrition and, consequently, sarcopenia. Nutritional management of sarcopenia in liver cirrhosis is a continuously evolving field and data on essential amino acid supplementation in chronic liver diseases is scarce. AREAS COVERED: This review encompasses the current literature on oral amino acids supplementation in patients with chronic liver disease or patients with liver cirrhosis to try to elucidate the possible effects of L-branched-chain amino acids and isolated L-leucine as a therapeutic approach to malnutrition and sarcopenia. EXPERT COMMENTARY: To ensure an optimal nutritional status and to reduce sarcopenia, it is necessary to assess nutritional status in all patients with liver cirrhosis and to apply nutritional interventions accordingly. The supply of calories, proteins, and essential amino acids is necessary for the maintenance of muscle mass and function. Although supplementation of L-branched-chain amino acids plays an important role in liver disease, L-leucine has been described as the main amino acid involved in protein turnover, reducing proteolysis, and stimulating protein synthesis.
Assuntos
Aminoácidos de Cadeia Ramificada/uso terapêutico , Leucina/uso terapêutico , Hepatopatias/tratamento farmacológico , Desnutrição/tratamento farmacológico , Sarcopenia/tratamento farmacológico , Administração Oral , Aminoácidos de Cadeia Ramificada/administração & dosagem , Doença Crônica , Suplementos Nutricionais , Progressão da Doença , Leucina/administração & dosagem , Hepatopatias/complicações , Desnutrição/etiologia , Proteólise/efeitos dos fármacos , Sarcopenia/etiologiaRESUMO
The improvement of malnutrition with levocarnitine in maintenance hemodialysis (MHD) patients is controversial. We performed a meta-analysis to evaluate the efficacy of levocarnitine in improving malnutrition in MHD patients. We performed a literature search for relevant articles related to the treatment of malnutrition by L-carnitine in MHD patients in PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang databases. We set the publication dates from 1950 to July 2019. The levels of albumin, prealbumin, total protein, and transferrin before and after treatment were used for assessing malnutrition. Twenty-seven studies were included in the present analysis. The results of the random effects model indicated that L-carnitine treatment improved the albumin level in patients on MHD patients. The pooled standardized mean difference of albumin level was 2.51 (95% confidence interval (CI): 2.13-2.90, P<0.001). The pooled total protein level was 3.83 (95% CI: 2.41-5.24, P = 0.000) and the pooled transferrin level was 0.35 (95% CI: 0.18-0.52, P = 0.000). Significant differences were observed with the total protein and transferrin levels. The results indicated that levocarnitine significantly improved the prealbumin level in patients on MHD. The pooled prealbumin level was 70.86 (95% CI: 42.99-98.73, P = 0.000). No publication bias was detected (P>0.05). The present meta-analysis indicated that L-carnitine can have a favorable effect on malnutrition biomarkers in patients on MHD, including the increase in albumin, total protein, transferrin, and prealbumin levels. The L-carnitine could be an option for treatment of MHD patients.
Assuntos
Carnitina/uso terapêutico , Suplementos Nutricionais , Nefropatias/terapia , Desnutrição/tratamento farmacológico , Estado Nutricional , Diálise Renal , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Carnitina/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Feminino , Humanos , Nefropatias/complicações , Nefropatias/diagnóstico , Masculino , Desnutrição/diagnóstico , Desnutrição/etiologia , Desnutrição/fisiopatologia , Pessoa de Meia-Idade , Pré-Albumina/metabolismo , Diálise Renal/efeitos adversos , Albumina Sérica Humana/metabolismo , Transferrina/metabolismo , Resultado do TratamentoRESUMO
BACKGROUND & AIMS: Malnutrition or undernutrition, arising from a deficiency of energy and protein intake, occurs commonly among community-dwelling individuals in developed countries. Once identified, malnutrition can be effectively treated in the majority of cases with dietary advice and the prescription of oral nutritional supplements (ONS) for patients who can eat and drink orally. However, previous research has reported inadequate screening and treatment of malnutrition in the community. The aim of this qualitative study was to explore general practitioners' (GPs) experiences and opinions on the management of malnutrition and the prescription of ONS in the primary care/community setting in Ireland. METHODS: Sixteen semi-structured interviews including chart stimulated recalls (CSR) were conducted with GPs. The interviews and CSRs explored, among others, the following domains; barriers and facilitators in the management of malnutrition, ONS prescribing in the primary care/community setting, and future directions in the management of malnutrition and ONS prescribing. Recorded interviews were transcribed and analysed following a generic qualitative approach with inductive thematic analysis using NVIVO 12 to facilitate data management. RESULTS: Three main themes were identified. Theme 1: 'Malnutrition is a secondary concern', encapsulating the idea that the identification of malnutrition is usually secondary to other clinical issues or disease rather than an independent clinical outcome. This theme also includes the idea that obesity is viewed as a dominant nutritional issue for GPs. Theme 2: 'Responsibility for malnutrition and ONS management in the community', highlighting that GPs feel they do not know who is responsible for the management of malnutrition in the community setting and expressed their need for more support from other healthcare professionals (HCPs) to effectively monitor and treat malnutrition. Theme 3: 'Reluctance to prescribe ONS', emerging from the GPs reported lack of knowledge to prescribe the appropriate ONS, their concern that ONS will replace the patient's meals and the costs associated with the prescription of ONS. CONCLUSIONS: GPs in Ireland do not routinely screen for malnutrition in their clinics as they feel unsupported in treating and managing malnutrition in the community due to limited or no dietetic service availability and time constraints. GPs also view malnutrition as a secondary concern to disease management and prioritise referral to dietetic services for patients with overweight and obesity. GPs reported that they have insufficient knowledge to change or discontinue ONS prescriptions. This study demonstrates that there is a clear need for primary care training in malnutrition identification, treatment and management and more community dietetic services are needed in order to support GPs and deliver high quality care to patients.
Assuntos
Suplementos Nutricionais , Clínicos Gerais , Desnutrição/diagnóstico , Desnutrição/tratamento farmacológico , Adolescente , Adulto , Idoso , Aconselhamento , Dietética , Feminino , Humanos , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Avaliação Nutricional , Obesidade , Sobrepeso , Prescrições , Atenção Primária à Saúde , Pesquisa Qualitativa , Adulto JovemRESUMO
BACKGROUND: Malaria is a worldwide problem that affects millions of people yearly. In rural areas where anti-malarial drugs are not easily accessible, many people use herbal treatments, such as Moringa oleifera, to treat a variety of diseases and ailments including malaria. While Moringa is reported to possess potent and curative anti-malarial properties, previous studies have mostly been restricted to assessment of parasitaemia. In this study, the effect of Moringa on malaria immunity in a murine model was investigated. METHODS: Using a high dose (60 mg/mouse) for a short time (7 days) or low dose Moringa (30 mg/mouse) for a longer time (3 weeks), cytokine production, and Tbet expression by effector CD4+ T cells (Teff) were determined. Mice were also treated with Moringa after infection (curatively) or before infection (prophylactically) to determine the effect of the plant extract on parasitaemia and immunity. Given that Moringa also possess many nutritional benefits, the contribution of Moringa on malnourished malaria infected mice was determined. Malnutrition was induced by limiting access to food to only 4 h a day for 4 weeks, while control mice had unlimited access to mouse laboratory chow. All data was collected by flow cytometry and analysed using one-Way ANOVA or two tailed Student's t test. RESULTS: Moringa-treated mice had increased numbers of effector CD4+ T cells accompanied by an increase in Tbet expression compared to control untreated mice. Mice that were treated with Moringa curatively also exhibited increased effector CD4+ T cell numbers, IFN-gamma and TNF secretion. Interestingly, the mice that were treated prophylactically had significantly higher Tbet expression. In the absence of adaptive immunity, high parasitaemia was observed in the RAG1 knockout mice. The food limited mice (malnourished) had reduced numbers of CD4+ T cells, TNF proportions, and significantly greater Tbet expression compared to the control group. Supplementation with Moringa in the limited group slightly restored CD4+ T cell activation, IL-2, and IL-10 production. CONCLUSIONS: Taken together, these data suggest that Moringa treatment leads to increased CD4+ T cell activation, Th1 differentiation and production of pro-inflammatory cytokines after malaria infection. Thus, Moringa may be immunologically useful in the treatment of malaria and malnutrition. Further investigations are required to identify the active components in Moringa.
Assuntos
Malária/tratamento farmacológico , Desnutrição/imunologia , Moringa oleifera/química , Plasmodium chabaudi/efeitos dos fármacos , Proteínas com Domínio T/metabolismo , Animais , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/metabolismo , Feminino , Citometria de Fluxo , Malária/complicações , Malária/imunologia , Desnutrição/complicações , Desnutrição/tratamento farmacológico , Camundongos , Camundongos Endogâmicos C57BL , Parasitemia/parasitologia , Extratos Vegetais/uso terapêutico , Folhas de Planta/química , Baço/citologia , Subpopulações de Linfócitos T/efeitos dos fármacosRESUMO
BACKGROUND: Malnutrition commonly occurs in patients with heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan, which is an AT1 neprilysin inhibitor, has been shown to reduce mortality and hospitalization in patients with HFrEF. However, its effects on nutritional status remain unclear. METHODS: Sacubitril/valsartan was initiated in 164 symptomatic patients with HFrEF receiving an optimal medical treatment with angiotensin inhibition (mean age: 63â±â20 years; 120 males, 60% ischemic cause). The New York Heart Association (NYHA) functional class and nutritional statuses of the patients were evaluated at the switching to AT1 neprilysin inhibitor and at the 6th-month follow-up of the maximum sacubitril/valsartan dose using the geriatric nutritional risk index (GNRI), controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), and prealbumin. RESULTS: After the sacubutril/valsartan treatment, a significant reduction in the number (%) of malnourished patients was observed according to CONUT (before 47% vs. after 7%, Pâ<â0.001), GNRI (before 39% vs. after 19%, Pâ<â0.001), PNI scores (before 36% vs. after 12%, Pâ=â0.002), and prealbumin (before 41% vs. after 12%, Pâ<â0.001). Also significant changes were observed at the baseline and follow-up in the mean scores of the three different nutritional indexes and prealbumin levels [CONUT: 2.68â±â2.5, 1.02â±â1.0 (Pâ<â0.001); GNRI: 97.1â±â9.7, 101.2â±â5.9 (Pâ<â0.001); PNI: 38.8â±â4.8, 41.6â±â3.7 (Pâ<â0.001); prealbumin: 14.6â±â6.9âmg/dl, 17.1â±â5.2âmg/dl (Pâ<â0.001)]. Overall, the patients exhibited a significant functional improvement following the initiation of sacubitril/valsartan: 23% of the patients improved by two NYHA classes, 48% improved by one NYHA class, and 39% remained stable. CONCLUSION: In patients with HFrEF, the switch from angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan resulted in a significant improvement in both nutritional and functional statuses.
Assuntos
Aminobutiratos/uso terapêutico , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Desnutrição/tratamento farmacológico , Estado Nutricional/efeitos dos fármacos , Inibidores de Proteases/uso terapêutico , Volume Sistólico/efeitos dos fármacos , Tetrazóis/uso terapêutico , Função Ventricular Esquerda/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Aminobutiratos/efeitos adversos , Bloqueadores do Receptor Tipo 1 de Angiotensina II/efeitos adversos , Compostos de Bifenilo , Combinação de Medicamentos , Substituição de Medicamentos , Feminino , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Desnutrição/diagnóstico , Desnutrição/fisiopatologia , Pessoa de Meia-Idade , Neprilisina/antagonistas & inibidores , Avaliação Nutricional , Estudos Prospectivos , Inibidores de Proteases/efeitos adversos , Recuperação de Função Fisiológica , Tetrazóis/efeitos adversos , Fatores de Tempo , Resultado do Tratamento , ValsartanaRESUMO
BACKGROUND & AIMS: Oral nutritional supplements (ONS) are commonly used to treat malnutrition. Many patients are prescribed ONS without assessment of nutritional status. This conflicts with prescribing guidelines and has considerable cost implications. This scoping review aimed to provide an overview of interventions to improve appropriate ONS prescribing in primary care. METHODS: A systematic scoping review was undertaken. PubMed, EMBASE and CINAHL were searched from inception to September 2018. Studies meeting inclusion criteria had to: evaluate interventions targeting ONS prescribing in primary care; use a comparative evaluation; be published in English. Two reviewers independently screened abstracts and extracted data relating to study design, intervention characteristics, outcome assessments and key findings. Extracted data were collated using figures, tables and accompanying descriptive summaries. RESULTS: 10 studies met inclusion criteria. All studies involved uncontrolled before-and-after designs. Interventions ranged from dietitian-led reviews of patients prescribed ONS to transfer of ONS prescribing privileges from general practitioners to dietitians. Post-intervention results showed improvements in ONS prescribing based on study-specific assessments of prescribing appropriateness and absolute reductions in prescribing, as well as potential cost-savings. CONCLUSIONS: This review provides a detailed overview of interventions aimed at improving appropriate ONS prescribing in primary care. Interventions evaluated to date most commonly involved dietitians. However, use of controlled experimental design was lacking. Lack of consistency in defining appropriate ONS prescribing and assessment outcomes was apparent. Future research should attend to rigour during intervention development, evaluation and reporting in order to generate findings which could inform relevant policy and practice.